Skip to main content
. 2022 Oct 22;74:111–121. doi: 10.1016/j.pcad.2022.10.004

Table 1.

Myocarditis incidence in patients with COVID-19.42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52

Study Design/Database Country Total COVID-19 patients Myocarditis incidence total (%) Risk/Odds ratio
Boehmer et al. 2021 Retrospective (Premier Healthcare Database Special COVID-19 Release) USA 1,452,773 2116 (0.146) RR 15.7; 95% CI 14.1–17.2)
Buckley et al. 2021 Retrospective (Global federated health research network) International 718,365 35,820 (5.0) RR, 18.28; 95% CI, 3.95 to 25.12
Barda et al. 2021 Retrospective (Clalit Health Services) Israel 173,106 19 (0.01) NA
Annie et al. 2021 Retrospective (TriNetX platform) USA 259,352 383 (0.2) NA
Murk et al. 2021 Retrospective (Health Verity's Marketplace data set) USA 70,288 70 (0.1) OR 8.17; 95% CI 3.58-18.62
Linschoten et al. 2020 Registry International 3011 3 (0.1) NA
Jalali et al. 2021 Retrospective (Single Center) Iran 196 15 (7.7) NA
Sang III et al. Autopsy USA 50 2 (4) NA
Kunal et al. 2020 Single Center Retrospective India 108 3 (2.8) NA
Bhatia et al. 2021 Registry Australia 644 2 (0.31) NA
Daniels et al. 2021 Registry (US Universities, Athletes only) USA 1597 37 (2.3) NA